Literature DB >> 24416567

Late rectal and bladder toxicity following radiation therapy for prostate cancer: Predictive factors and treatment results.

Rafael Fuentes-Raspall1, José Maria Inoriza2, Alvaro Rosello-Serrano1, Carmen Auñón-Sanz1, Pilar Garcia-Martin2, Gemma Oliu-Isern2.   

Abstract

AIM: This study aimed at investigating factors associated to late rectal and bladder toxicity following radiation therapy and the effectiveness of Hyperbaric Oxygen Therapy (HBOT) when toxicity is grade ≥2.
BACKGROUND: Radiation is frequently used for prostate cancer, but a 5-20% incidence of late radiation proctitis and cystitis exists. Some clinical and dosimetric factors have been defined without a full agreement. For patients diagnosed of late chronic proctitis and/or cystitis grade ≥2 treatment is not well defined. Hyperbaric Oxygen Therapy (HBOT) has been used, but its effectiveness is not well known.
MATERIALS AND METHODS: 257 patients were treated with radiation therapy for prostate cancer. Clinical, pharmacological and dosimetric parameters were collected. Patients having a grade ≥2 toxicity were treated with HBOT. Results of the intervention were measured by monitoring toxicity by Common Toxicity Criteria v3 (CTCv3).
RESULTS: Late rectal toxicity was related to the volume irradiated, i.e. V50 > 53.64 (p = 0.013); V60 > 38.59% (p = 0.005); V65 > 31.09% (p = 0.002) and V70 > 22.81% (p = 0.012). We could not correlate the volume for bladder. A total of 24 (9.3%) patients experienced a grade ≥2. Only the use of dicumarinic treatment was significant for late rectal toxicity (p = 0.014). A total of 14 patients needed HBOT. Final percentage of patients with a persistent toxicity grade ≥2 was 4.5%.
CONCLUSION: Rectal volume irradiated and dicumarinic treatment were associated to late rectal/bladder toxicity. When toxicity grade ≥2 is diagnosed, HBOT significantly ameliorate symptoms.

Entities:  

Keywords:  Bladder toxicity; Hyperbaric oxygen; Predictive factors; Radiotherapy; Rectal toxicity; Treatment

Year:  2013        PMID: 24416567      PMCID: PMC3863251          DOI: 10.1016/j.rpor.2013.05.006

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  26 in total

Review 1.  Radiation injury of the rectum.

Authors:  P C O'Brien
Journal:  Radiother Oncol       Date:  2001-07       Impact factor: 6.280

2.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.

Authors:  Deborah A Kuban; Susan L Tucker; Lei Dong; George Starkschall; Eugene H Huang; M Rex Cheung; Andrew K Lee; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-31       Impact factor: 7.038

3.  Hyperbaric oxygen--an effective tool to treat radiation morbidity in prostate cancer.

Authors:  R Mayer; H Klemen; F Quehenberger; O Sankin; E Mayer; A Hackl; F M Smolle-Juettner
Journal:  Radiother Oncol       Date:  2001-11       Impact factor: 6.280

4.  Hyperbaric oxygen therapy for radionecrosis of the jaw: a randomized, placebo-controlled, double-blind trial from the ORN96 study group.

Authors:  Djillali Annane; Joël Depondt; Philippe Aubert; Maryvonne Villart; Pierre Géhanno; Philippe Gajdos; Sylvie Chevret
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

5.  Diabetes mellitus: a predictor for late radiation morbidity.

Authors:  D M Herold; A L Hanlon; G E Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-02-01       Impact factor: 7.038

6.  Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response.

Authors:  M W Skwarchuk; A Jackson; M J Zelefsky; E S Venkatraman; D M Cowen; S Levegrün; C M Burman; Z Fuks; S A Leibel; C C Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-04-01       Impact factor: 7.038

Review 7.  Hyperbaric oxygen therapy for late radiation tissue injury.

Authors:  M H Bennett; J Feldmeier; N Hampson; R Smee; C Milross
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

8.  Clinical correlations between treatment with anticoagulants/antiaggregants and late rectal toxicity after radiotherapy for prostate cancer.

Authors:  Ken Takeda; Yoshihiro Ogawa; Hisanori Ariga; Masashi Koto; Toru Sakayauchi; Keisuke Fujimoto; Kakutaro Narazaki; Masatoshi Mitsuya; Yoshihiro Takai; Shogo Yamada
Journal:  Anticancer Res       Date:  2009-05       Impact factor: 2.480

9.  Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.

Authors:  Michael J Zelefsky; Emily J Levin; Margie Hunt; Yoshiya Yamada; Alison M Shippy; Andrew Jackson; Howard I Amols
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-15       Impact factor: 7.038

Review 10.  A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach.

Authors:  J J Feldmeier; N B Hampson
Journal:  Undersea Hyperb Med       Date:  2002       Impact factor: 0.698

View more
  9 in total

Review 1.  A Practical Approach to the Management of Radiation-Induced Hemorrhagic Cystitis.

Authors:  Xavier Liem; Fred Saad; Guila Delouya
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

2.  Long term clinical toxicity of radiation therapy in prostate cancer patients with Inflammatory Bowel Disease.

Authors:  Matthew M Gestaut; Gregory P Swanson
Journal:  Rep Pract Oncol Radiother       Date:  2016-11-25

3.  Postoperative radiotherapy in prostate cancer: Analysis of prognostic factors in a series of 282 patients.

Authors:  Giuseppina Apicella; Debora Beldì; Giansilvio Marchioro; Sara Torrente; Sara Tunesi; Corrado Magnani; Alessandro Volpe; Carlo Terrone; Marco Krengli
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-01

4.  Influence of optimizing protocol choice on the integral dose value in prostate radiotherapy planning by dynamic techniques - Pilot study.

Authors:  Anna Zaleska; Krzysztof Bogaczyk; Tomasz Piotrowski
Journal:  Rep Pract Oncol Radiother       Date:  2017-08-17

5.  Comparison between Conventional IMRT Planning and a Novel Real-Time Adaptive Planning Strategy in Hypofractionated Regimes for Prostate Cancer: A Proof-of-Concept Planning Study.

Authors:  Maria Antico; Peter Prinsen; Alice Fracassi; Alfonso Isola; David Cobben; Davide Fontanarosa
Journal:  Healthcare (Basel)       Date:  2019-12-02

6.  Aplastic anemia associated with severe hemorrhagic cystitis following radiotherapy for prostate cancer.

Authors:  Taito Nakano; Kouji Izumi; Aerken Maolake; Ariunbold Natsagdorji; Hiroaki Iwamoto; Yasuhide Kitagawa; Yoshifumi Kadono; Hiroyuki Konaka; Atsushi Mizokami; Mikio Namiki
Journal:  Mol Clin Oncol       Date:  2016-02-25

7.  Why we should take care of the competing risk bias in survival analysis: A phase II trial on the toxicity profile of radiotherapy for prostate cancer.

Authors:  Annarita Tullio; Alessandro Magli; Eugenia Moretti; Francesca Valent
Journal:  Rep Pract Oncol Radiother       Date:  2019-08-19

Review 8.  A Ten-year-long Update on Radiation Proctitis Among Prostate Cancer Patients Treated With Curative External Beam Radiotherapy.

Authors:  Gianluca Ferini; Stefano Pergolizzi
Journal:  In Vivo       Date:  2021-04-28       Impact factor: 2.406

9.  Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study.

Authors:  Mauro Gacci; Omar Saleh; Claudia Giannessi; Beatrice Detti; Lorenzo Livi; Eleonora Monteleone Pasquetti; Tatiana Masoni; Enrico Finazzi Agro; Vincenzo Li Marzi; Andrea Minervini; Marco Carini; Stavros Gravas; Matthias Oelke; Sergio Serni
Journal:  BMC Urol       Date:  2015-07-07       Impact factor: 2.264

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.